Biogen (NASDAQ: BIIB) reported a 3% decline in total revenue for Q3 2024, totaling $2.5 billion, alongside a 6% drop in non-GAAP diluted EPS to $4.08. Despite these declines, the company highlighted strong sequential growth in key product launches, particularly LEQEMBI, which saw a 66% increase in global revenue quarter-over-quarter, and SKYCLARYS, which is now generating revenue in 15 countries outside the U.S. The firm also raised its 2024 non-GAAP EPS guidance to a range of $16.10–$16.60, reflecting an expected 11% growth at the midpoint.
The mixed results underscore ongoing challenges in Biogen’s multiple sclerosis (MS) product revenues, which fell approximately 9% due to competitive pressures, and SPINRAZA, which saw a 15% decline primarily from lost Russian tender revenues. However, the company’s focus on cost controls and R&D prioritization has led to improved operating margins and a robust free cash flow of $901 million, the highest since Q2 2021.
Investors should monitor Biogen’s ability to sustain growth through its emerging pipeline, which has a potential peak revenue of $14 billion, as well as the continued uptake of its new therapies amid evolving market dynamics and reimbursement processes.
Source: fool.com